Trevi Therapeutics Inc (TRVI)
2.72
+0.04
(+1.49%)
USD |
NASDAQ |
Apr 19, 15:53
Trevi Therapeutics Cash from Operations (TTM): -31.71M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -31.71M |
September 30, 2023 | -31.68M |
June 30, 2023 | -32.98M |
March 31, 2023 | -29.28M |
December 31, 2022 | -28.18M |
September 30, 2022 | -28.07M |
June 30, 2022 | -26.74M |
March 31, 2022 | -28.46M |
December 31, 2021 | -28.95M |
September 30, 2021 | -31.64M |
June 30, 2021 | -31.37M |
Date | Value |
---|---|
March 31, 2021 | -31.90M |
December 31, 2020 | -29.00M |
September 30, 2020 | -26.28M |
June 30, 2020 | -27.04M |
March 31, 2020 | -23.67M |
December 31, 2019 | -23.09M |
September 30, 2019 | -21.62M |
June 30, 2019 | -17.88M |
March 31, 2019 | -18.43M |
December 31, 2018 | -18.29M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-32.98M
Minimum
Jun 2023
-17.88M
Maximum
Jun 2019
-27.87M
Average
-28.46M
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
Accuray Inc | 19.82M |
Vanda Pharmaceuticals Inc | 12.80M |
NovaBay Pharmaceuticals Inc | -4.131M |
Palatin Technologies Inc | -26.54M |
iBio Inc | -18.89M |